The CCRM industry consortium represents key sectors of the Regenerative Medicine (RM) industry – pharmaceutical, devices, reagents, tools, biomaterials and cell therapies and consists of large multinationals, small-medium enterprises (SME) and emerging biotechnology companies. It provides market knowledge and a ready supply of global receptors for technologies and products generated by CCRM and its partners. The benefits of Australian companies becoming a member of the Industry consortium include:

  • Increased brand recognition and awareness
  • Access to potential customers at an international level
  • Access to Intellectual Property (IP)
  • Thought leadership
  • Collaborative development and advancement of project ideas, and
  • Increased engagement with the broader regenerative medicine community
  • Product development team to augment academic expertise and facilities
  • International industry consortium that reconciles technology push with market pull
  • Network of local and international business and scientific leaders

Being part of CCRM Australia offers:

  • For Industry: Access to state-of-art discoveries, facilities and expertise in Australia and through the CCRM global network. Access to clinical trial networks.
  • For Academics: Business leaders and corporate partners to accelerate commercialization drawn from an international pool
  • For Investors: risk-mitigated and capital-efficient product development


To learn more about CCRM Australia, download our brochure:
What Is CCRM Australia